About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global Expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information ESG Contact us
Products Services
Product center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Career
Talent R&D Team Employee Life Job Opportunities
EN
CN
About Us
· Company Introduction · Strategic Development · Social Responsibility
Scientific Research
· Innovative Layout · Innovative Field
Products Services
· Product center · Product branding · Quality & Safety
News
· Company News · Media Coverage · Media Inquiries · Multimedia zone
Vocational
· Concept about Talent · R&D Team · Employee Life · Job Opportunities
> News > Company
Return
COVID-19 Prevention and Control Should Ensure
2020-04-01

Grandpharma (China) Co., Ltd. salutes every healthcare worker who fought to save lives and solve difficulties in the front line. Thank you for putting up a wall against the epidemic for the people of the whole country and bringing us out of the darkest hour of the epidemic, showing us a bright and vibrant spring. Referring to the National Guidelines for the Diagnosis and Treatment of COVID-19 and the consensus of clinical experts during the epidemic prevention and control period, Grandpharma collected and sorted out the drugs related to COVID-19, and collected them into drug packs for treatment options in case of emergency. Non-professionals should read the drug instructions carefully and consult a medical professional, and follow the doctor’s advice before taking related drugs. The drugs in “ANTI-NCP Protection Package” covers anti-virus, anti-infection, expectorant, anti-oxidation, intestinal microbial regulation, detoxification, immune regulation and eye care, etc., among which the raw materials of antiviral drug “hydroxychloroquine sulfate” are produced by Grandpharma and other products (except diammonium glycyrrhizinate, vitamin C and zinc sulfate) are also produced by Grandpharma (China) Co., Ltd. and its associated enterprises within the group.  

 

The further we travel, the greater we value the health. Grandpharma (China) Co., Ltd. wishes the people in motherland and around the world stay healthy and safe!

Prev

Next

Related news

  • <em>The Phase IIa Clinical Study Conducted in China of Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment</em>
    The Phase IIa Clinical Study Conducted in China of Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment

    2025-10-26

  • The Registration Clinical Study Conducted in China of the Global Innovative Temperature-Sensitive Embolic Agent Has Completed All Patients Enrollment
    The Registration Clinical Study Conducted in China of the Global Innovative Temperature-Sensitive Embolic Agent Has Completed All Patients Enrollment

    2025-10-09

  • Grand Pharma’s Treprostinil Injection Has Been Granted a Drug Registration Certificate by NMPA
    Grand Pharma’s Treprostinil Injection Has Been Granted a Drug Registration Certificate by NMPA

    2025-09-24

Grand Pharma Group
About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information Contact us
Products Services
Product Center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Vocational
Concept about Talent R&D Team Employee Life Job Opportunities
Copyright © Grand Pharma (China) Co., Ltd. All Rights Reserved E ICP B 10008288 EGWAB 42010402000597
Legal Provisions